Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

• ABP-671 plus febuxostat Group 1 (Drug): ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)
• ABP-671 plus febuxostat Group 2 (Drug): ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)
• ABP-671 Group (Drug): ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)
• Placebo Group (Drug): ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)

Primary outcomes

• The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baseline [Week 40]

Secondary outcomes

• The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baseline [Week 16]
• Incidence of treatment-emergent adverse events (Safety and Tolerability) [Week 40]: Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation

Sex: All, ages: 18 Years to 75 Years

Inclusion Criteria:

* Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study
* Patients who have been diagnosed with CKD based on Clinical Practice Guideline
* During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg/m2
* The sUA levels > 420 μmol/L (7.0 mg/dL)

Exclusion Criteria:

* History of renal transplantation
* The 24-hour urinary protein ≥ 3.5 g/day
* Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase > 3 times the upper limit of normal value (ULN)
* Subjects with mental disorders who are unable to communicate normally with the investigator
* Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study
* The investigator judged that the subject was not suitable for participation in this study